brodalumab

FDA Drug Profile

Drug Details

Generic Name
brodalumab
Brand Names
N/A
Application Number
Sponsor
Patheon Italia S.p.A.
NDC Codes
1
Dosage Forms
INJECTION
Routes
N/A
Active Ingredients
BRODALUMAB

Indications and Usage

1 INDICATIONS AND USAGE SILIQ ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. SILIQ is a human interleukin-17 receptor A (IL-17RA) antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. ( 1 )